U.S. Biologics Manufacturing Market Size & Outlook

Name: U.S. Biologics Manufacturing Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The biologics manufacturing market in the United States is expected to reach a projected revenue of US$ 54,638.6 million by 2033. A compound annual growth rate of 16.4% is expected of the United States biologics manufacturing market from 2026 to 2033.

Biotechnology
- Bioprocessing
  - Biologics Manufacturing Market Outlook

U.S. biologics manufacturing mode of manufacturing outlook (Revenue, USD million, 2021-2033)
- Contract Manufacturing
- In-house manufacturing
U.S. biologics manufacturing modality outlook (Revenue, USD million, 2021-2033)
- Monoclonal Antibodies (mAbs)
- Biosimilar & Recombinant Proteins
- Vaccines (recombinant/mRNA/Viral)
- Cell & Gene Therapies
- RNA-based Therapeutics
- Others
U.S. biologics manufacturing disease indication outlook (Revenue, USD million, 2021-2033)
- Oncology
- Autoimmune Disorders
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Disorders
- Other Disease Indications

U.S. Biologics Manufacturing Market Size & Outlook

Data Tree

Sign up - it's easy, and free!